Beijing-based METiS TechBio is exploring the potential of treating aging as a software bug, leveraging AI to address genetic errors in human cells.
According to CEO Lai Tsai-ta, aging can be likened to the accumulation of errors in a complex software system, particularly in the DNA sequences of cells. He suggests that AI could play a crucial role in "reading, rewriting, and reversing" these cellular errors, which may ultimately slow the aging process. A focus on rejuvenating immune cells, especially T cells, is highlighted as essential since their functionality diminishes with age, increasing susceptibility to diseases like cancer.
With a keen eye on the burgeoning longevity market, METiS TechBio has developed AI-driven nano-delivery platforms that target specific cells and organs for drug delivery. The company recently raised $269.5 million in its IPO in Hong Kong, with substantial backing from major investors like BlackRock and UBS Asset Management Singapore.
As cellular reprogramming emerges as a leading frontier in longevity science, AI is enhancing biotech firms' capabilities to model human biology and discover new life-extending therapies. While still in its infancy, the field has seen rapid advancements, particularly in the U.S., which leads globally in cellular reprogramming, accounting for a significant share of investment and deal volume in the sector.
This innovative approach could redefine our understanding of aging and health, positioning AI not just as a tool for treatment but as a transformative force in longevity research.